Nov. 30 (Bloomberg) -- Ranbaxy Laboratories Ltd., India’s biggest drugmaker, won U.S. clearance to sell a generic version of Pfizer Inc.’s $10.7 billion Lipitor cholesterol pill.
The Food and Drug Administration approved Ranbaxy’s copy of the world’s top-selling drug, which will be manufactured by Ohm Laboratories in New Brunswick, New Jersey, the agency said today in a statement. Watson Pharmaceuticals Inc. today began selling a copy of Lipitor in the U.S. under an agreement with New York- based Pfizer. Watson’s version didn’t require FDA clearance because Pfizer is providing the drug to sell without the brand label in return for a share of the revenue.
--With assistance from Drew Armstrong in New York and Adi Narayan in Mumbai. Editors: Andrew Pollack, Bruce Rule
To contact the reporter on this story: Molly Peterson in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Adriel Bettelheim at email@example.com